Related Experiment Videos
Mucolytics for bronchiectasis
A J Crockett1, J M Cranston, K M Latimer
1Respiratory Unit, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, AUSTRALIA, 5042. alan.crockett@flinders.edu.au
The Cochrane Database of Systematic Reviews
|May 2, 2001
Summary
Limited evidence supports mucolytics for bronchiectasis. High-dose bromhexine with antibiotics may improve sputum clearance in bronchiectasis patients. Further research is needed.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Bronchiectasis is an irreversible airway dilation often leading to difficulty clearing infected sputum.
- Mucolytic agents aim to improve sputum properties for easier expectoration.
- Recombinant human DNase targets DNA from neutrophils at infection sites.
Purpose of the Study:
- To review the efficacy of ingested or inhaled mucolytics for managing bronchiectasis.
Main Methods:
- Searched multiple databases and contacted experts for relevant randomized trials.
- Included trials on mucolytic treatment for bronchiectasis, excluding cystic fibrosis.
- Independent data extraction and author verification were performed.
Main Results:
- Three trials were identified; meta-analysis was not possible.
- High-dose bromhexine with antibiotics improved sputum expectoration and reduced production compared to placebo.
- Recombinant human DNase showed no benefit and potentially negative effects on lung function, with increased adverse events.
Conclusions:
- Insufficient evidence exists for routine mucolytic use in bronchiectasis.
- High-dose bromhexine combined with antibiotics may aid sputum clearance.
- More research is required to establish the role of mucolytics in bronchiectasis management.